Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress - Ibi Daisuke; Takaba Rika; Yoshida Keisuke; Kawase Ririna; Kitagawa Hiroko; Matsushita Momoko; Ito Kana; Uno Shoya; Nishimura Fumiya; Kitagaki Shinji; Hiramatsu Masayuki (Neuropsychopharmacology Reports, 2026)

Phase 1 trial suggests benefit of psilocybin in OCD treatment (The Brown University Psychopharmacology Update, 2026)

Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development - Enriquez-Geppert Stefanie; Bevers Lisa; Rosander Arvid; Fodran Peter; Polito Vince (Biomolecules, 2026)

Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventions - Whitfield Henry J.; Schepers Jan; Mason Natasha L.; Luca Maria; Kuypers Kim P. C. (Journal of Psychedelic Studies, 2026)

Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions - Amiel Sharchaton; Shilat Parsha; Sara P. Azerrad; Yaron Dekel; Nisreen Rabah; Tomáš Páleníček; Eyal Kurzbaum (Journal of Fungi, 2026)

Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions. - Koning E; Richard J; Keshen A. (International Journal of Eating Disorders, 2026)

Sexual identity as a moderator of associations between lifetime MDMA/ecstasy or psilocybin use and mental health outcomes: An exploratory analysis of a nationally representative sample using NSDUH 2015-2019 - Seale M. (Research Square, 2026)

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study - University of Wisconsin; Madison (ClinicalTrials.gov, 2026)

Psilocybin helps woman with Alzheimer's - Busby Mattha (New Scientist, 2026)

Convergent biosynthesis of psilocybin in an ectomycorrhizal lineage: is the psychoactive end-product the selected trait? - Askari M; Surapaneni V. (EcoEvoRxiv, 2026)

Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms - Hummel Haley M.; Obrochta Alexia N.; Kerr David C. R.; Cservenka Anita (Journal of Drug Issues, 2026)

Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review. - Smith SA; Mohammad H; Lee LHN; Dennett L; Smith S; Burback L; Winkler O; Greenshaw A; Jetly R; Kennedy SH; Bhat V; Swainson J; et al. (2026)

Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms - Centre Hospitalier Universitaire de Nīmes (ClinicalTrials.gov, 2026)

A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD) - Sunstone Medical (ClinicalTrials.gov, 2026)

Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits. - Pasquini L; Vohryzek J; Escrichs A; Perl YS; Ponce-Alvarez A; Idesis S; Girn M; Roseman L; Mitchell JM; Gazzaley A; Kringelbach M; Nutt DJ; et al. (Human Brain Mapping, 2026)

Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review - Jalalian-Javadpour Marzieh; Yekta Batool Ghorbani; Reyhani Niloufar; Hajizamani Shadi; Azizi Ali; Azad Najma Khoshrooz; Mohammadi Hamidreza; Vaseghi Salar (Journal of Affective Disorders Reports, 2026)

Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders. - Plourde L; Chang SL; Nguyen O; Garel N; Farzin H; Stephan JF; Fallu JS; Dorval M; P3A Research Group (Palliative medicine, 2026)

Psilocybin induces stereotyped movements and reduces defensive responding in planarians through 5-hydroxytryptamine mechanisms. - Akbar RJ; Stringer AD; Wiah S; Dachepalli M; Daws SE; Inan S; Rawls SM. (2026)

MFCC-DFT mapping of ligand recognition at the 5-HT2A receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics. - Junior WSC; Bezerra KS; Matias EGC; Oliveira JIN; Fulco UL. (2026)

Chemistry/structural biology of psychedelic drugs and their receptor(s). - Gumpper RH; Nichols DE (British journal of pharmacology, 2026)

Psilocybin as a novel treatment for chronic pain. - Askey T; Lasrado R; Maiarú M; Stephens GJ (British journal of pharmacology, 2026)

The Australia story: Current status and future challenges for the clinical applications of psychedelics. - Nutt DJ; Hunt P; Schlag AK; Fitzgerald P (British journal of pharmacology, 2026)

Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT receptor agonists. - Sharp T; Ippolito A (British journal of pharmacology, 2026)

Psychedelics, entactogens and psychoplastogens for depression and related disorders. - Hoyer D (British journal of pharmacology, 2026)

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation? - Qureshi O; Cowley J; Pegg A; Cooper AJ; Gordon J; Brady CA; Belli A; Butterworth S; Upthegrove R; Andrews N; Barnes NM (British journal of pharmacology, 2026)

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology. - Wittenkeller L; Gudelsky G; Winhusen TJ; Amato D (British journal of pharmacology, 2026)

Correction: The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice. - Fleury S; Nautiyal KM. (2026)

Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway. - Ascone F; Buzzelli V; Mottarlini F; Di Trapano M; Miglioranza P; Rava A; Feo A; Spano F; Hausman M; Sugaya K; Caffino L; Fumagalli F; et al. (Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 2026)

Three cases of wood-lover paralysis: clinical insights from Victoria, Australia. - Silvester A; Hampton S; May TW; Holmes GD; Leang YH (Clinical toxicology (Philadelphia, Pa.), 2026)

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants. - Arikci D; Borgulya J; Straumann I; Vizeli P; Luethi D; Thomann J; Rudin D; Vukalovic I; Eckert A; Liechti ME; Holze F (Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 2026)

A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults - University of Colorado; Denver (ClinicalTrials.gov, 2026)

The relevance of the 5HT2A-mGlu2 heterodimer in explaining the clinical ambivalence of psilocybin - Escobar-Cornejo Guillermo; Corredor-Gamba Julián; Rodriguez-Rojas Yoly; Cárdenas F. P. (Revista de Neuro-Psiquiatría, 2026)

Study Protocol for "Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults". - Sjöström D; Schau Rybäck O; Claesdotter Knutsson E; Kajonius P; Jensen Sondén O; Carlbring P; Björkstrand J; Movahed Rad P. (PLoS ONE, 2026)

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats. - Ladislavová L; Kútná V; Mazochová K; Šíchová K; Danda H; Lhotková E; Uttl L; Brejtr V; Syrová K; Mazoch V; Horsley R; Páleníček T. (2026)

Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development - Stefanie Enriquez Geppert; Lisa Bevers; Arvid Rosander; Peter Fodran; Vince Polito (University of Groningen research database (University of Groningen / Centre for Information Technology), 2026)

MDMA and psilocybin therapy rules have been relaxed. Here’s what might happen next - Thileepan Naren; Suzanne Nielsen; Myfanwy Graham (2026)

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease - Yale University (ClinicalTrials.gov, 2026)

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder - Johns Hopkins University (ClinicalTrials.gov, 2026)

Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex. - Du Y; Zhao X; Yao Y; Li Y; Wang G; Zhang L. (Journal of Psychopharmacology, 2026)

Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial - Unity Health Toronto (ClinicalTrials.gov, 2026)

Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)] - University of California; San Diego (ClinicalTrials.gov, 2026)

Divergent changes in perturbation-induced brain reconfiguration following depression treatment with psilocybin and escitalopram - Dagnino; P. C.; Acero-Pousa; I.; Carhart-Harris; R.; Erritzoe; D.; Nutt; D. J.; Kringelbach; M. L.; Sanz Perl; Y.; Deco; G. (bioRxiv, 2026)

Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2026)

A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD) - Anthony P King (ClinicalTrials.gov, 2026)

Psilocybin Administration With 5-HT1a Blockade - Johns Hopkins University (ClinicalTrials.gov, 2026)

The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential. - Brar PS; Price RB; Ross S; Tofighi B; Sarpal DK (Journal of psychopharmacology (Oxford, England), 2026)

Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions. - Guidetti C; Fava M; Papakostas GI. (2026)

TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy - M.D. Anderson Cancer Center (ClinicalTrials.gov, 2026)

TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors - M.D. Anderson Cancer Center (ClinicalTrials.gov, 2026)

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy - M.D. Anderson Cancer Center (ClinicalTrials.gov, 2026)

Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study - Yale University (ClinicalTrials.gov, 2026)

Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial - University Health Network; Toronto (ClinicalTrials.gov, 2026)

Psilocybin-Assisted Therapy for Prolonged Grief - University of Virginia (ClinicalTrials.gov, 2026)

Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim test - Lenka Seillier; Alexandre Seillier; Morgan A. Zvolska; Romana Šlamberová (Journal of Psychopharmacology, 2026)

Cardiovascular effects associated with acute recreational drug toxicity presentations to the emergency department: a European drug emergencies network (Euro-DEN plus) study. - van den Busken WJ; Dines AM; Eyer F; Heyerdahl F; Hovda KE; Liechti ME; Miró Ò; Vallersnes OM; Wood DM; Yates C; Dargan PI; (on behalf of the Euro-DEN Plus Research Group); et al. (Clinical toxicology (Philadelphia, Pa.), 2026)

Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids - Roswell Park Cancer Institute (ClinicalTrials.gov, 2026)

Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy - Johns Hopkins University (ClinicalTrials.gov, 2026)

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label Trial - University Health Network; Toronto (ClinicalTrials.gov, 2026)

Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes - Frick A; Blest-Hopley G; Grin M; Erritzoe D; Nutt D; Carhart-Harris R. (Research Square, 2026)

Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidence - Astrit Sabani; Adnan Khatak (Annals of Medicine and Surgery, 2026)

DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in Zebrafish - Mengxuan Dong; Yi Zhang; Manzhu Cao; Tong Shi; Liqin Li; Xingxing Zong; Chen Wang (Molecules, 2026)

“I even saw four deer grazing”: online-offline entanglements in the psilocybin pluriverse - Michał Wanke; Paweł Matuszewski; Piotr Siuda (2026)

Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico - Lawrence Leeman; Maya Armstrong; Dara Menashi; Hanifa Nayo-Washington; Elliot Marseille; Janus Herrera; Crystal Romero; Janet Page-Reeves (Frontiers in Public Health, 2026)

Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics. - Bhat A; Zolali E; Sakib MA; Rahimian M; McMahon LR; German N; Obeng S (ACS chemical neuroscience, 2026)

Distinct brain responses to psilocybin and escitalopram in depression captured by the Fluctuation-Dissipation Theorem - Dagnino PC; Acero-Pousa I; Zamora-López G; Escrichs A; Erritzoe D; Nutt DJ; Carhart-Harris RL; Sanz Perl Y; Kringelbach ML; Deco G. (bioRxiv, 2026)

The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function - Manoj Doss (ClinicalTrials.gov, 2026)

Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial - Brigham; Women's Hospital (ClinicalTrials.gov, 2026)

Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARA - SAIMSARA (SAIMSARA Journal, 2026)

Efficacy of Psilocybin-Assisted Therapy in Major Depressive Disorder: A Systematic Review and Meta-Analysis - Angel Labra-Lorenzana; Dania Nimbe Lima Sanchez; Christian Alejandro Delaflor-Wagner; Diana Martínez-Hernández; Christian Ramos-Jiménez; Christian Gabriel Toledo-Lozano (Psychiatry International, 2026)

Unmixing the Psychedelic Connectome: Brain Network Traits of Psilocybin - Bhavaraju Kirshna Prasad; Mason Natasha L.; Mallaroni Pablo; Heinke Dietmar; Toennes Stefan W.; Ramaekers Johannes G.; Amico Enrico (Network Neuroscience, 2026)

Genome-based optimization of psilocybin and N,N-dimethyltryptamine biosynthetic pathways in E. coli using CRISPR-associated transposases - Zachary N. Abrahms; Mohammad Majdi; Siena M. Madsen; Chloe J. Morton; Abhishek K. Sen; Niya B. Fried; Lily E. Sawyer; Evelyn R. Cegielski; Sean J. Spezzano; J. Andrew Jones (Metabolic Engineering, 2026)

Balancing safety and access in Oregon’s psilocybin services - Katherine Cheung; Caleigh Propes; David B. Yaden (International Journal of Drug Policy, 2026)

Barriers and Facilitators for Psychedelic Research and Regulation in Brazil: Insights From Diverse Stakeholders. - Guimarães AL; Beserra FR; Cruz L; Bienemmann B; Freind JMK; Guinle V; Rodrigues RS; Regalado JA; Mograbi DC (Clinical therapeutics, 2026)

Altered States, Enhanced Potential: Psychedelics and Physical Performance (PsyArXiv, 2026)

EEG microstate dynamics during psilocybin intoxication relate to acute experience and persisting psychological changes - Jajcay N; Vejmola Č; Korčák J; Tylš F; Viktorinová M; Viktorin V; Bravermanová A; Androvičová R; Balíková M; Horáček J; Brunovský M; Hlinka J; et al. (bioRxiv, 2026)

Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depression - J. Mingardi; R. Molteni; F. Bifari (Pharmacological Research, 2026)

Aquahenosis: A non-pharmacological altered state of consciousness induced by Floatation-REST in individuals with anxiety and depression (PsyArXiv, 2026)

Psilocybin as a Treatment for Chronic Pain in Smokers - Yale University (ClinicalTrials.gov, 2026)

Psilocybin-assisted Physiotherapy for Refractory Motor Functional Neurological Disorder: A Randomized Dose-comparison Pilot Study (P7-17.001) - Alexander Bryson; Chiranth Bhagavan; O. Carter; Glenn Nielsen; David Berlowitz; Sara Issak; Zachary Attard; Dina Eleftheriadis; Gina Oliver; Deanne Mayne; Greg Roebuck; James Rucker; et al. (Neurology, 2026)

PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment - Johns Hopkins University (ClinicalTrials.gov, 2026)

A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease - Jennifer Mitchell (ClinicalTrials.gov, 2026)

Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-sampling - Robin Carhart-Harris; PhD; MA (ClinicalTrials.gov, 2026)

A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans - VA Office of Research; Development (ClinicalTrials.gov, 2026)

Correction to: Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action - Matthew J. Reid; Hannes Kettner; Tessa F. Blanken; Brandon Weiss; Robin Carhart-Harris (Current Psychiatry Reports, 2026)

Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticity - Samaneh Ahmadian-Moghadam; Shiva Roshan-Milani; Ehsan Saboory (Translational Psychiatry, 2026)

Developing Methods for Observing Awe Narration in Psilocybin-Assisted Therapy - Elise C. Tarbi; Ian Bhatia; Nabil Balach; Suzannah Buehler; Magdalena Demeo-Meres; Cailin Gramling; Tej Thambi; Julia Hart; Maija Reblin; Donna M. Rizzo; Robert Gramling; Manish Agrawal; et al. (Healthcare, 2026)

Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study - Yale University (ClinicalTrials.gov, 2026)

2 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy Volunteers - Robin Carhart-Harris; PhD; MA (ClinicalTrials.gov, 2026)

Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression - Cecelia Kelly; Mathieu Fradet; Catherine M. Bostian; Anna Donnelly; Sara Ellis; Michael Ostacher; Scott Aaronson; Trisha Suppes (Journal of Affective Disorders, 2026)

Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus - Shuhan Lu; Zhixin Zhang; Xinmiao Xue; Yuke Jiang; Chi Zhang; Peng Liu (120506); Dongdong He; Shen Weidong; Shiming Yang; Fangyuan Wang (Hearing Research, 2026)

Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation - Michel Dorval; Virginie Audet-Croteau; Sue-Ling Chang; Marianne Masse-Grenier; Annie Tremblay; Elodie Bénard; Alexandra Chapdelaine; Nicolas Garel; Jason Robert Guertin (Healthcare, 2026)

The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults - University of Calgary (ClinicalTrials.gov, 2026)

Prolonged Grief Symptom Outcomes During At-Home Ketamine-Assisted Therapy: A Real-World Retrospective Analysis of 503 Adults - Carter D; Reardon I; Swain J; Vando L. (Research Square, 2026)

Time to embrace the whole: considering the replacement of psilocybin with Psilocybe spp. in psychedelic research and therapy - Genís Oña; Cristina Llagostera; Oscar Alvarez; Rosa M. Dueñas; Débora González; Óscar Soto-Angona (Natural Product Research, 2026)

Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST) - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2026)

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD) - Usona Institute (ClinicalTrials.gov, 2026)

Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder - University of Pennsylvania (ClinicalTrials.gov, 2026)

Patient perceptions towards psychedelics for musculoskeletal pain: A cross-sectional survey - Li EJ; Mosharraf B; Ali H; Noyes M; Doshi P; Wallace C; Petranker R; Adili A; Khan M; Busse JW; MacKillop J; Madden K. (medRxiv, 2026)

Corrigendum to “From Prohibited to Prescribed: The Rescheduling of MDMA and Psilocybin in Australia” (Drug Science Policy and Law, 2026)

EE127 A REVIEW OF HEALTH ECONOMIC ANALYSES OF PSILOCYBIN, MIDOMAFETAMINE(MDMA), AND KETAMINE-BASED TREATMENTS FOR MENTAL HEALTH CARE - Matthew Sidovar; Shane J. O’Connor; Lucinda Orsini (Value in Health, 2026)

EE341 COST-EFFECTIVENESS OF PSILOCYBIN-ASSISTED THERAPY (PAT) FOR PATIENTS WITH TREATMENT-RESISTANT DEPRESSION - Yosr Ziadi; Taehwan Park (Value in Health, 2026)

Psilocybin Decreases Preference for Large Rewards Accompanied by Increased Activity of Parvalbumin Neurons With Perineuronal Nets in the Medial Prefrontal Cortex - Jenna Houff; Andrew Williams; Obie Allen; Barbara Gisabella; Harry Pantazopoulos; Alberto Del Arco (European Journal of Neuroscience, 2026)

Reorganization of Human Brain Waves Across Diverse States of Consciousness - Fotiadis P; Jang H; Dai R; Li D; Cofré R; Timmermann C; Mashour GA; Hudetz AG; Huang Z. (bioRxiv, 2026)

Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats - Josh Allen; Bianca Jupp; Tamara L. Baker; Mohammad B. Haskali; Robert Brkljača; Zoe Plummer; Mujun Sun; Justin Brand; Brian R. Christie; Chantel T. Debert; Stuart J. McDonald; Terence J. O’Brien; et al. (Cell Reports Medicine, 2026)

A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression - University of Washington (ClinicalTrials.gov, 2026)

Psilocybin shows rapid relief for depression symptoms - Valerie A. Canady (Mental Health Weekly, 2026)

Psilocybin shows mixed results for patients with treatment-resistant depression (The Brown University Psychopharmacology Update, 2026)

Single-dose psilocybin with CBT more effective than nicotine patch for smoking cessation (The Brown University Psychopharmacology Update, 2026)

Effect of psilocybin-assisted psychotherapy on anxiety symptoms: A systematic review and meta-analysis - Alex Hood; Gary ELKINS (Journal of Psychedelic Studies, 2026)

Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache - Kristoffer Brendstrup-Brix; Brice Ozenne; Patrick M. Fisher; Dea S. Stenbæk; Anja S. Petersen; Sophia Armand; Drummond E-Wen. McCulloch; Maja Rou Marstrand-Joergensen; Sara M. Ulv Larsen; Annette Johansen; R O B V Jensen; Gitte M. Knudsen; et al. (Journal of Psychopharmacology, 2026)

A spatiotemporal gating hypothesis for psilocybin plasticity: reconciling the 5-HT₂A-TrkB mechanistic paradox - Gang Pei (Cell Discovery, 2026)

Psychedelic-induced hypomania and mania: a systematic review and meta-analysis. - Eskinazi M; Nasserdine R; Cusin RM; Baniotoupoulos P; Saccaro LF; De Pieri M; Corino T; Seragnoli F; Briefer JF; Aboulafia Brakha T; Richard-Lepouriel H; Penzenstadler L; et al. (2026)

Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers. - L Belinger; N M Rieser; E J E Engeli; L Becciolini; M Clamote; M Pribis; F Saissi; G.A. Florineth; N L Hehl; M Herdener; K H Preller (Open Access CRIS of the University of Bern, 2026)

Rapid and Sensitive Detection of Psilocybin and Psilocin in Urine by Surface-Enhanced Raman Spectroscopy - Lin Wei; Hong Chen; Yuanyuan Li (Journal of Raman Spectroscopy, 2026)

Psilocybin-induced neurocardiogenic syncope: a case report - Mazen A. Atiq; Eli Weisman; Rodrigo B. Guerra; Luis Luna Martinez; David B. Yaden; Frederick S. Barrett; Sandeep Nayak; Ceyda Sayalı (Psychopharmacology, 2026)

Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration: a case report - Marcos Lago; Mariana Cerveira; Joe Xavier Simonet (Frontiers in Neuroscience, 2026)

Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia - NYU Langone Health (ClinicalTrials.gov, 2026)

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial - Lea J. Mertens; Felix Betzler; Manuela Brand; Ricarda Evens; Andrea Jungaberle; Henrik Jungaberle; Laura Kärtner; Tomislav Majić; Christian N. Schmitz; Andreas Ströhle; Dennis Scharf; Moritz Spangemacher; et al. (Psychotherapy and Psychosomatics, 2026)

Catatonia Associated With First-Time Psilocybin Exposure: A Case Report - Jasbir Singh; Pranathi Mruthyunjaya (Cureus, 2026)

Studies on enzymatic hydrolysis of psilocin- O -glucuronide for screening of psilocin in human urine by liquid chromatography-triple quadrupole tandem mass spectrometry - David A Barajas; Heather C Noda Carter; Michael R Tomedi; Hiu Yu Lam; Tiffany N Deloatch; Gregory D Reynolds; Marisol S. Castaneto; Pucheng Ke (Journal of Analytical Toxicology, 2026)

The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD - Emory University (ClinicalTrials.gov, 2026)

Environmental and Internal Gating of Memory: ARCH Multiplicative Threshold Framework for Encoding and Retrieval - Rahman T. (Preprints.org, 2026)

Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder. - Urban MM; Zillich L; Rieser NM; Herdener M; Spanagel R; Vollenweider FX; Preller KH; Meinhardt MW. (2026)

Mystery shopper assessments of cannabis retailer practices and regulatory compliance in five U.S. states, 2025. - Berg CJ; LoParco CR; Rossheim ME; McCready DM; Langan L; Platt E; Romm KF; Johnson M; Speer MB; Burris S; Cavazos-Rehg PA. (2026)

Overcoming Pharmacokinetic and Peripheral Safety Challenges in Psychedelic Therapies: The Promise of Advanced Drug Delivery Systems. - Zhang T; Lin C; Wang X. (2026)

Serotonergic Psychedelics as a Potential Therapeutic Strategy for Anxiety, A Systematic Review (PsyArXiv, 2026)

Psilocybin for Treatment-Resistant Depression: A Comprehensive Review of Mechanisms and Therapeutic Potential - Dallas T Mason (Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg), 2026)

The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A New and Promising Approach - Rachel N Clark (Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg), 2026)

Psilocybin-Assisted Therapy in the Management of Anxiety and Depression Among Cancer Patients - Caleb Lemus (Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg), 2026)

A single dose of psilocybin eased depression symptoms for months, our study found - Hampus Yngwe; J O Lundberg (2026)

Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot Trial - University of Colorado; Denver (ClinicalTrials.gov, 2026)

Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder - University of New Mexico (ClinicalTrials.gov, 2026)

PsiConnect: Multimodal Neuroimaging of Context-Dependent Brain and Behaviour Dynamics under Psilocybin - Leonardo Novelli; Devon Stoliker; Tamrin Barta; Matthew D. Greaves; Sidhant Chopra; James Jackson; Jessica Kwee; James C. Pang; Martin L. Williams; Adeel Razi (Scientific Data, 2026)

A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression - Washington University School of Medicine (ClinicalTrials.gov, 2026)

265 Self-reported rates of psilocybin use in North Florida, 2012 to present - Millay T; Kodali M; Cottler L. (2026)

361 Effect of intravenous psilocybin on mechanical hypersensitivity in a rat model of reserpine-induced chronic centralized pain - Huels E; Smith S; Liu T; Pal D. (2026)

Psilocybin-assisted Cognitive Behavioral Therapy for Depression - University of California; Los Angeles (ClinicalTrials.gov, 2026)

Psilocybin-facilitated Treatment for Cocaine Use - University of Alabama at Birmingham (ClinicalTrials.gov, 2026)

Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2026)

Appetite for change: How psilocybin reshapes food reward learning through striatal dopamine function - Conn K; Wong N; Sunnetci S; Al Siyabi A; McCoy K; Huang K; Greaves E; Milton LK; Kuhlmann L; Maguire S; Foldi CJ. (bioRxiv, 2026)

Corrigendum to: “Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscape” (Australian & New Zealand Journal of Psychiatry, 2026)

Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression - Hampus Yngwe; Pontus Plavén-Sigray; Carl Johan Ekman; Eva Henje; Anders Berglund; Mikael Tiger; Maria Beckman; J O Lundberg (JAMA Network Open, 2026)

Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY) - Alan Davis (ClinicalTrials.gov, 2026)

Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence - University of Calgary (ClinicalTrials.gov, 2026)

Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial. (PsyArXiv, 2026)

Psilocybin-Assisted Therapy for Adolescent Anorexia Nervosa: Clinical Considerations and Emerging Models of Care - Jamarie Geller; Rachel Pacilio; Amanda E. Downey; Anya Ragnhildstveit; Marissa Raymond-Flesch; Stephanie Knatz-Peck; Natalie Gukasyan (Current Psychiatry Reports, 2026)

Ethical Complexities and Best Practices in Informed Consent Processes for Psilocybin Services: A Qualitative Study - Christina Chwyl; Alissa Bazinet; Adrianne R. Wilson-Poe; Kim Hoffman; Kellie Pertl; R. Cameron Wolf; P. Todd Korthuis; Jason B. Luoma (Neuroethics, 2026)

Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization - Feliciano Yu; Joe Tafur; Francisco Moreno; Stephen Dahmer (Frontiers in Psychiatry, 2026)

A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. - Francisco A Moreno (ClinicalTrials.gov, 2026)

Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based Sample - University of Wisconsin; Madison (ClinicalTrials.gov, 2026)

A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder - COMPASS Pathways (ClinicalTrials.gov, 2026)

Rapid-acting interventions in treatment-resistant depression - a comparative review of esketamine and psilocybin - Bartłomiej Kosiarski; Anna Skrzypek; Patrycja Markowicz; Mikołaj Zbrożek; Krzysztof Biłyk; Maciej Hutkowski; Zuzanna Chwostek; Hanna Maruchniak; Wiktoria Marzec; Paulina Biedroń (Journal of Pre-Clinical and Clinical Research, 2026)

Demoralization in Psilocybin-Assisted Therapy for Advanced Cancer: An Exploratory Network Analysis - Austin Mallard; Jessica Harbour; Catherine Pappano; Mary Mancuso; Kristin Kilbourn; Stacy M. Fischer (Journal of Pain and Symptom Management, 2026)

Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation - Andrew van der Vaart; Jeffrey LaPratt; Kimberly Swartz; Audrey Shoultz; Margo Lauterbach; Trisha Suppes; Harold A. Sackeïm; Scott T. Aaronson (The Journal of Clinical Psychiatry, 2026)

Safety and Efficacy of Psilocybin in the Management of Treatment-Resistant Depression: A Systematic Review - Walters CK; Chetty S; Rants’o TA; Gossayn S; Lerotholi LJ. (Research Square, 2026)

The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD. - University Medical Center Groningen (ClinicalTrials.gov, 2026)

Characterizing Resting-State Brain Dynamics with Frequency-Resolved EEG Microstates: Parallel Analyses of Psilocybin Microdosing and Acute Inhaled DMT - Tarailis P; Griskova-Bulanova I. (bioRxiv, 2026)

Neural correlates of insight on psilocybin: a within-subjects, healthy volunteer study - Lorenzo Pasquini; Manesh Girn; Hannes Kettner; Avery Ostrand; Kate Allison; Christian Valtierra; Will Lucas; Patrick McConnell; Catriona Miller; Sydney Griffith; Dawn Weinstein; B L Anderson; et al. (2026)

Does Psilocybin Require Psychedelic Effects to Treat Depression? A4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2026)

Psilocybin-Assisted Therapy in Depressive Disorders: Efficacy, Safety, and Persistence of Clinical Effects - A Narrative Review - Kinga Zachar; Maksymilian Sito; Filip Jurkowski; Łukasz Wójcik; Natalia Gawron; Hubert Tomasz Bojanowski; Aleksandra Dobracka; Zuzanna Marczak; Monika Jarowicz; Jędrzej Czmyr (Journal of Education Health and Sport, 2026)

Psilocybin in the Treatment of Cocaine Use Disorder - Peter S. Hendricks; Sara Lappan; Richard C. Shelton; Adrienne C. Lahti; Karen L. Cropsey; Matthew W. Johnson; Melissa Bradley; Otto Simonsson; Lori L. Davis; Daniel H. Grossman; Cynthia E. Ortiz (JAMA Network Open, 2026)

Pilot Results for Psilocybin-Assisted Psychotherapy for Cocaine Use Disorder-A Critical Appraisal - Erin E Bonar (JAMA Network Open, 2026)

Magic mushroom compound shows promise against cocaine addiction. - Nuwer R (Science (New York, N.Y.), 2026)

The magic of mushrooms: psilocybin influences behavior in the mangrove rivulus fish, Kryptolebias marmoratus - Dayna Forsyth; Nicoletta Faraone; Simon G. Lamarre; Suzanne Currie (Frontiers in Behavioral Neuroscience, 2026)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer - Sunstone Medical (ClinicalTrials.gov, 2026)

Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study - University of North Carolina; Chapel Hill (ClinicalTrials.gov, 2026)

A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder - Stanford University (ClinicalTrials.gov, 2026)

An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress in People With Pancreatobiliary and Other Advanced Gastrointestinal Cancers - University of Nebraska (ClinicalTrials.gov, 2026)

Human brain changes after first psilocybin use. - Lyons T; Spriggs M; Kerkelä L; Rosas FE; Roseman L; Mediano PAM; Timmermann C; Oestreich L; Pagni BA; Zeifman RJ; Hampshire A; Trender W; et al. (2026)

A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control - Usona Institute (ClinicalTrials.gov, 2026)

A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression - University of Washington (ClinicalTrials.gov, 2026)

Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury - James J. Peters Veterans Affairs Medical Center (ClinicalTrials.gov, 2026)

Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder - University of California; Los Angeles (ClinicalTrials.gov, 2026)

Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults - Kevin H. Yang; Nora Satybaldiyeva; Wayne Kepner; Joseph Friedman; Siyuan Ping; Eric C. Leas (American Journal of Preventive Medicine, 2026)

Effects of Psilocybin Treatment on Cognitive Effort Avoidance in Major Depressive Disorder and Co-Occurring Alcohol Use Disorder - Ceyda Sayalı; Eli Weisman; Frederick Barrett (2026)

Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial - Lakshmi N Yatham (ClinicalTrials.gov, 2026)

Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects - Yale University (ClinicalTrials.gov, 2026)

Sa1731 A PILOT STUDY OF OPEN-LABEL PSILOCYBIN-ASSISTED THERAPY IN TREATMENT-REFRACTORY IBS - Erin Mauney; Juliana Zambrano; Jenna Clukey; Helen Burton-Murray; Michael Datko; Vitaly Napadow; Braden Kuo; Franklin King (Gastrointestinal Endoscopy, 2026)

Sex-Specific Effects of Psilocin on Paraventricular Nucleus of the Thalamus (PVT) Circuitry and Threat Responding Behavior in Male and Female Rats - Herman Melissa (Biological Psychiatry, 2026)

Prohedonic Effects of Psilocybin (COMP360) in a Touchscreen-Based Rodent Probabilistic Reward Task (Abstract ID: 227883) - Kayleigh LaMalfa; Diego A. Pizzagalli; Jack Bergman; Christopher W. Thomas; Brian Kangas (Journal of Pharmacology and Experimental Therapeutics, 2026)

1020 Long-term Impact of Psilocybin Administration on Sleep-Continuity via Wearable Sensor Time-series: Preliminary-results in Post-Treatment Lyme Disease - Matthew Reid; Abigail Yaffe; Ian Geithner; Alison Rebman; John Aucott; Albert Garcia-Romeu (SLEEP, 2026)

PDE4B Inhibition and Psilocybin as Promising Approaches for Treating Methamphetamine Use Disorder: Preclinical Evidence From Rat Models (Abstract ID: 232554) - Sean Hayduk; Amy Stringer; Satoria Zagorski; Sara Jane Ward (Journal of Pharmacology and Experimental Therapeutics, 2026)

Pure psilocybin reduces reward-associated preference while mushroom extract shows transient exploratory effects in rats (RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia, 2026)

C29-12 Psilocybin Treatment Could Improve Outcomes for Age-associated Lung Diseases - L Hecker; J M Kleinhenz; C Coarfa; K Kato (American Journal of Respiratory and Critical Care Medicine, 2026)

Prevalence and Correlates of Past-Year Psilocybin Use in the U.S., 2024, USA - R Andrew Yockey; Amber Amis; Elise Devier; Aminul Apu; Rachel Hoopsick (AJPM Focus, 2026)

Effects of Psilocybin on Attentional Set-Shifting Following Chronic Unpredictable Stress in Rats (Abstract ID: 231339) - Joseph Hennessey; John Mantsch; John McCorvy (Journal of Pharmacology and Experimental Therapeutics, 2026)

Preclinical evaluation of psilocybin and related compounds: Inhibition of cytochrome P450 isoforms (RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia, 2026)

1080 Psilocybin Elicits Non-Linear Night to Night Changes in Sleep Spectral Power - Matthew Reid; Eli Weisman; Luis Luna Martinez; William Coon; Frederick Barrett (SLEEP, 2026)

SAT-219 Hepatic 5-HT2B receptor antagonism mediates the anti-steatotic and antifibrotic effects of psilocybin in preclinical MASH models - Anna Signor; Martina Colognesi; Giovanna Finzi; Daniela Gabbia; Andrea Mattarei; Stefano Comai; Gianfranco Pasut; Franco Folli; Paolo Manfredi; Sara De Martin (Journal of Hepatology, 2026)

Cytochrome P450 Inhibition by Psilocybin and Psilocin: A Combined Molecular Dynamics and Enzymatic Screening Study (RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia, 2026)

0408 Insomnia Severity Differences by Psilocybin, LSD, and DMT Use Status Among Young Adult Daily Cannabis Consumers in the Herbal Heart Study - Denise Vidot; Bria-Necole Diggs; Amrit Baral; Michelle Thompson; Girardin Jean-Louis (SLEEP, 2026)

Role of Psychological support in sustaining Antidepressants effects in Psilocybin - Assisted Clinical - Gyandev Gupta; Ravina Yadav (JOURNAL OF ADVANCE AND FUTURE RESEARCH, 2026)

Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review. - Viljoen G; Walter H; Bendau A; Koslowski M; Betzler F (Journal of psychopharmacology (Oxford, England), 2026)

Trip killers: Addressing a critical knowledge gap in psychedelic research. - O'Mahony B; Harrington C; Harkin A; Lally N (Journal of psychopharmacology (Oxford, England), 2026)

Associations between psychedelic use and migraine history in Swedish twins. - Simonsson O; Sun S; Wesseldijk LW; Ullén F; Osika W; Mosing MA (Journal of psychopharmacology (Oxford, England), 2026)

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM - Zeina Beidas; Anya Ragnhildstveit; Adam Blackman; Thomas Anderson; Emily Fewster; Omer A. Syed; Valentyne Sobolenko; Ismail Kaan Kanca; Tatiana Son; Norman Farb; Rotem Petranker (BJPsych Open, 2026)

Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled Settings - Kurt Stocker; Matthias Hartmann; Frederick S. Barrett; William A. Richards; Nathan D. Sepeda; Laura Ley; Anna M. Becker; Friederike Holze; Matthias E. Liechti (Repository for Publications and Research Data (ETH Zurich), 2026)

Characterizing psilocybin’s effects on nociception and thermoregulation in preclinical pain models - Tyler Girard; Boris Heifets; Robert Sapolsky; X Chen; Stanford University (Stanford Digital Repository, 2026)

Does Psychological Flexibility Correlate with Mystical Experiences: A Machine Learning Approach Including State of Surrender, Near-Death Experiences, and Psilocybin Consumption - Dylan Briggs; Thomas B. Sease; Ruthie Menou; David R. Perkins (Behavioral Sciences, 2026)

Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study) - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2026)